RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer

Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed RANK and RANKL protein expression in more than 2,000 breast tumors (777 estrogen receptor‐negative, ER−) from four independent cohorts. RANK protein expression was more frequent in ER− tumors, where it associated with poor outcome and poor response to chemotherapy. In ER− breast cancer patient‐derived orthoxenografts (PDXs), RANKL inhibition reduced tumor cell proliferation and stemness, regulated tumor immunity and metabolism, and improved response to chemotherapy. Intriguingly, tumor RANK protein expression associated with poor prognosis in postmenopausal breast cancer patients, activation of NFKB signaling, and modulation of immune and metabolic pathways, suggesting that RANK signaling increases after menopause. Our results demonstrate that RANK protein expression is an independent biomarker of poor prognosis in postmenopausal and ER− breast cancer patients and support the therapeutic benefit of RANK pathway inhibitors, such as denosumab, in breast cancer patients with RANK+ ER− tumors after menopause.

[1]  P. Fasching,et al.  Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. , 2022, JAMA oncology.

[2]  M. Serrano,et al.  RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing tumor aggressiveness , 2021, Developmental cell.

[3]  C. Sotiriou,et al.  Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells , 2020, Nature Communications.

[4]  G. Mills,et al.  Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts , 2020, Clinical Cancer Research.

[5]  F. Perrone,et al.  Denosumab in early breast cancer: negative data and a call to action. , 2019, The Lancet. Oncology.

[6]  H. Iwata,et al.  Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[7]  A. Farooki,et al.  Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer. , 2019, British journal of clinical pharmacology.

[8]  R. Greil,et al.  Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial. , 2018 .

[9]  D. Pisano,et al.  Nextpresso: Next Generation Sequencing Expression Analysis Pipeline , 2017, Current Bioinformatics.

[10]  K. Edlund,et al.  RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer , 2017, Genes & development.

[11]  P. Kostenuik,et al.  Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells , 2017, Scientific Reports.

[12]  F. Climent,et al.  Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population , 2017, Stem cell reports.

[13]  J. Serra-Musach,et al.  RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation. , 2016, Cancer research.

[14]  A. Wardley,et al.  Patient-derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to Metastasis , 2016, Journal of Mammary Gland Biology and Neoplasia.

[15]  John W. Cassidy,et al.  A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds , 2016, Cell.

[16]  J. Visvader,et al.  RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers , 2016, Nature Medicine.

[17]  E. Guney,et al.  FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies , 2015, Oncotarget.

[18]  C. Sotiriou,et al.  RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy , 2015, Breast Cancer Research.

[19]  C. Denkert,et al.  RANK expression as a prognostic and predictive marker in breast cancer , 2014, Breast Cancer Research and Treatment.

[20]  Sakae Tanaka,et al.  A review of denosumab for the treatment of osteoporosis , 2014, Patient preference and adherence.

[21]  G. Ball,et al.  Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers , 2013, British Journal of Cancer.

[22]  M. Lewis,et al.  Establishment of Patient‐Derived Xenograft (PDX) Models of Human Breast Cancer , 2013, Current protocols in mouse biology.

[23]  S. Khosla,et al.  Estrogen and the skeleton , 2012, Trends in Endocrinology & Metabolism.

[24]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[25]  Jeremy Wazny,et al.  Xenome—a tool for classifying reads from xenograft samples , 2012, Bioinform..

[26]  F. Climent,et al.  RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. , 2012, Cancer research.

[27]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[28]  Mark T. W. Ebbert,et al.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.

[29]  Mitch Dowsett,et al.  Current and emerging biomarkers in breast cancer: prognosis and prediction. , 2010, Endocrine-related cancer.

[30]  D. Branstetter,et al.  RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis , 2010, Nature.

[31]  M. Widschwendter,et al.  Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer , 2010, Nature.

[32]  C. Clarke,et al.  Progesterone induces adult mammary stem cell expansion , 2010, Nature.

[33]  M. Smalley.  Isolation, culture and analysis of mouse mammary epithelial cells. , 2010, Methods in molecular biology.

[34]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[35]  Ian O Ellis,et al.  Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[37]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[38]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[39]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.